Latest News and Press Releases

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Preclinical data demonstrates that Shape’s engineered AAV5 variant, SHP-DB1, efficiently targets the NHP brain after intravenous injection and transduces >95% of neurons in the Parkinson's...

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval and Positive Interim Clinical Data for LX2006 in FA Cardiomyopathy

Groundbreaking study demonstrates that targeted oligodendrocyte gene therapy leads to decreased N-acetylaspartate (NAA) levels and increased brain myelin.

Shape Therapeutics to present at the ESGCT 32nd congress on an RNA-targeting gene therapy for Parkinson's Disease and a novel CNS AAV capsid.

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

New breakthrough data from studies with Coave’s ALIGATER™-engineered AAV2-based capsid coAAV-CSF-01 (S01coAAV2) demonstrates improved brain tissue transduction and safety following intra-cerebrospinal...

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting